Abstract
The human papillomavirus (HPV)-16/18 vaccine (Cervarix®) is a prophylactic vaccine for the prevention of cervical cancer. The vaccine contains recombinant virus-like particles assembled from the L1 major capsid proteins of the cervical cancer-causing viral types HPV-16 and HPV-18, and Adjuvant System 04 (AS04), which contains the immunostimulant MPL and aluminium salt. To evaluate potential local and systemic toxic effects of the HPV-16/18 vaccine or AS04 alone, three repeated-dose studies were performed in rabbits and rats. One rabbit study also included a single-dose evaluation. In rabbits (~2.5 kg), the full human dose (HD) of the vaccine was evaluated (0.5 ml per injection site), and in rats (~250 g), 1/5 HD of vaccine was evaluated, corresponding to ≥ 12 times the dosage in humans relative to body weight. In both animal models, the treatment-related changes included a slight transient increase in the number of circulating neutrophils as well as a local inflammatory reaction at the injection site. These treatment-related changes were less pronounced after four doses of AS04 alone than after four doses of the HPV-16/18 vaccine. Additional treatment-related changes in the rat included lower albumin/globulin ratios and microsc...Continue Reading
References
Feb 17, 2001·Journal of Applied Toxicology : JAT·K H DiehlUNKNOWN European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods
Feb 28, 2003·Acta Tropica·UNKNOWN WHO Informal Working Group
Jul 23, 2004·Expert Opinion on Biological Therapy·Jory R BaldridgeDavid Persing
Aug 10, 2004·Journal of Applied Toxicology : JAT·Paul BaldrickStefan R Woroniecki
Jan 22, 2005·Vaccine·François VerdierElisabeth Sauzeat
Sep 29, 2005·Immunology Letters·James M Brewer
Apr 18, 2006·Neuromuscular Disorders : NMD·François-Jérôme AuthierRomain Gherardi
Sep 29, 2006·Journal of Virology·Andres F MejiaNeil D Christensen
Apr 4, 2007·International Journal of Cancer. Journal International Du Cancer·Jennifer S SmithGary M Clifford
Aug 1, 2008·Cellular and Molecular Life Sciences : CMLS·C R Casella, T C Mitchell
Nov 26, 2008·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·L David WiseBrian J Ledwith
Jan 13, 2009·Virology·Harald zur Hausen
Feb 18, 2009·Human Vaccines·Dominique DescampsGary Dubin
Jul 10, 2009·Lancet·J PaavonenUNKNOWN HPV PATRICIA Study Group
Oct 30, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Arnaud M DidierlaurentNathalie Garçon
Sep 14, 2010·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·L David WiseJayanthi J Wolf
Sep 21, 2010·Reproductive Toxicology·Lawrence SegalMarguerite Deschamps
Oct 19, 2010·Human Vaccines·Michel DeschuyteneerMarguerite Deschamps
Apr 30, 2011·Vaccine·Nathalie GarçonMarcelle Van Mechelen
Nov 15, 2011·The Lancet Oncology·Matti LehtinenUNKNOWN HPV PATRICIA Study Group
Aug 28, 2012·The Lancet Infectious Diseases·Talía MalagónMarc Brisson